Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2024 / Articles / Oct / EFPIA Signs Up to Bolster EU Trade
Business & Regulation Business Practice Supply Chain Supply Chain

EFPIA Signs Up to Bolster EU Trade

EFPIA signs joint declaration championing open trade in the EU.

By Rob Coker 10/29/2024 1 min read

Share

A joint declaration by various EU-based trade organizations has been announced, with the aim of championing open trade for a prosperous future. The European Federation of Pharmaceutical Industries and Associations (EFPIA) is one notable signatory among 42 others. With an emphasis on the critical role of open trade in fostering economic growth, job creation, and resilience for the EU, the declaration reinforces the reasons why trade continues to provide more choice for consumers and more competition for businesses, as well as attract foreign investors.

The overall focus of the declaration on open trade, market access, and regulatory cooperation is relevant to all industries, including pharmaceuticals. Key areas of the declaration include diversification in sourcing and exports to increase resilience to global crises; removal of trade barriers; and greater regulatory cooperation. It advocates for a robust and forward-looking EU trade policy and a dedicated trade commissioner.

Collage Images: AdobeStock.com

Free Trade Agreements (FTAs) to enhance market access, reduce non-tariff barriers, and foster regulatory cooperation are crucial for the pharmaceutical industry. The declaration also includes an emphasis on intellectual property rights protection, which will align with the industry's need to safeguard innovation.

Moreover, the push for stronger cooperation between the EU, third countries, and private sectors, along with trade diplomacy, suggests that the pharmaceutical industry could stand to benefit from more streamlined processes and opportunities to engage with regulatory bodies and trade missions. These measures could also enhance the industry's ability to export products globally and tap into new markets.

The coalition says it will be using diplomacy to avoid potential political tensions through several key strategies, including an emphasis on the importance of trade diplomacy to prevent and resolve disputes and barriers. It encourages the use of trade missions, regulatory cooperation, and dialogue between the EU and its trade partners to promote EU products, share best practices, and prevent misunderstandings in trade relationships.

Through these strategies, the coalition seeks to promote an ambitious trade agenda while minimizing political tensions by focusing on economic benefits, cooperation, and adherence to established international rules.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Rob Coker

Following a Bachelor’s degree in English Literature and a Master’s in Creative Writing, I entered the world of publishing as a proofreader, working my way up to editor. The career so far has taken me to some amazing places, and I’m excited to see where I can go with Texere and The Medicine Maker.

More Articles by Rob Coker

False

Advertisement

Recommended

False

Related Content

What Trump’s Latest Moves Mean for the Industry
Business Practice Standards & Regulation Trends & Forecasts Bioprocessing - Upstream & Downstream
What Trump’s Latest Moves Mean for the Industry

May 27, 2025

6 min read

Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”, and an ever-shifting regulatory environment.

Big Bad Pharma?
Business Practice Trends & Forecasts
Big Bad Pharma?

December 1, 2014

0 min read

The Ebola media frenzy has reminded the public how selfish our industry is. But, somehow, that doesn’t sound quite right...

Access All Areas
Business Practice Trends & Forecasts
Access All Areas

December 1, 2014

0 min read

The 2014 Access to Medicine index shows progress – but companies remain “conservative”

Care to ‘Patent Dance’?
Business Practice Trends & Forecasts
Care to ‘Patent Dance’?

December 1, 2014

0 min read

Amgen accuses Sandoz of snubbing its advances in a complex biosimilar dispute

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.